|




Gilead Misses Analysts' Estimates on Sales of HIV Drugs

Gilead Misses Analysts' Estimates on Sales of HIV Drugs: Gilead shares rose 79 percent last year, the most since 1995, as sales of of HIV drugs increased and optimism built about its experimental hepatitis C therapies leading a $20 billion market. Sales of the treatments in the U.S. alone may reach $6.5 ...

Top stories of the last 30 days